SELLAS Life Sciences Group Inc (NASDAQ: SLS) on Monday, soared 12.31% from the previous trading day, before settling in for the closing price of $1.95. Within the past 52 weeks, SLS’s price has moved between $0.77 and $2.12.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 45.94%. The company achieved an average annual earnings per share of 36.67%. With a float of $97.67 million, this company’s outstanding shares have now reached $99.78 million.
The extent of productivity of a business whose workforce counts for 15 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
SELLAS Life Sciences Group Inc (SLS) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of SELLAS Life Sciences Group Inc is 2.11%, while institutional ownership is 14.33%. The most recent insider transaction that took place on Jun 12 ’25, was worth 14,800. In this transaction Director of this company bought 10,000 shares at a rate of $1.48, taking the stock ownership to the 20,400 shares. Before that another transaction happened on May 30 ’25, when Company’s Director bought 20,000 for $1.69, making the entire transaction worth $33,800. This insider now owns 30,400 shares in total.
SELLAS Life Sciences Group Inc (SLS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 36.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.56% during the next five years compared to 45.94% growth over the previous five years of trading.
SELLAS Life Sciences Group Inc (NASDAQ: SLS) Trading Performance Indicators
SELLAS Life Sciences Group Inc (SLS) is currently performing well based on its current performance indicators. A quick ratio of 4.64 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.39, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.38 in one year’s time.
Technical Analysis of SELLAS Life Sciences Group Inc (SLS)
The latest stats from [SELLAS Life Sciences Group Inc, SLS] show that its last 5-days average volume of 6.15 million was superior to 2.6 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 92.44%.
During the past 100 days, SELLAS Life Sciences Group Inc’s (SLS) raw stochastic average was set at 97.64%, which indicates a significant increase from 96.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 86.09% in the past 14 days, which was higher than the 74.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6300, while its 200-day Moving Average is $1.2900. Now, the first resistance to watch is $2.3000. This is followed by the second major resistance level at $2.4200. The third major resistance level sits at $2.6100. If the price goes on to break the first support level at $1.9900, it is likely to go to the next support level at $1.8000. The third support level lies at $1.6900 if the price breaches the second support level.
SELLAS Life Sciences Group Inc (NASDAQ: SLS) Key Stats
Market capitalization of the company is 218.51 million based on 99,777K outstanding shares. Right now, sales total 0 K and income totals -30,880 K. The company made 0 K in profit during its latest quarter, and -5,810 K in sales during its previous quarter.
